

REVA to Hold Fourth Quarter and Full Year 2017 Financial Results Call

San Diego, California and Sydney, Australia (Thursday, 1 March 2017 - AEST) – REVA Medical, Inc. (ASX: RVA) ("REVA" or the "Company") has scheduled a conference call to review its fourth quarter and full year 2017 financial results and provide a business update.

The call is scheduled for 8:30 a.m. AEST on Thursday, 8 March 2017 (which is 1:30 p.m. US PST on Wednesday, March 7, 2017) and may be accessed toll-free within Australia by dialing 1800 005 989 five minutes prior to the scheduled start time. Callers in the United States and Canada may access the call by dialing 1-877-312-5413. The conference ID is 1986218 for all locations.

If you reside outside of Australia, the United States, or Canada, or if you prefer to access the call through our website, please visit "Events & Presentations" under the "Investors" section of our website at www.revamedical.com, and click on the "listen to webcast" link. A live webcast and transcript of the call will also be available on our website.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company's lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.

Fantom and Fantom Encore are trademarks of REVA Medical, Inc.

United States
Investor & Media Enquiries:
REVA Medical, Inc.
Brandi Roberts
Chief Financial Officer
+1 858-966-3003
Cheryl Liberatore
Director, Communications
+1 858-966-3045
ir@revamedical.com

Australia Investor Enquiries: Inteq Limited Kim Jacobs +61 438 217 279 Andrew Cohen +61 408 333 452 Australia Media Enquiries: Buchan Consulting Rebecca Wilson +61 3 9866 4722